{"schema_version":"secwatch.filing_event.v1","accession":"0001013762-23-003541","form_type":"8-K","ticker":"SXTP","cik":"0001946563","company_name":"60 DEGREES PHARMACEUTICALS, INC.","filed_at":"2023-10-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.442054+00:00","generated_at":"2026-06-10T01:12:21.153857+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"60 Degrees suspends Phase IIB tafenoquine COVID-19 study; pivots to malaria and babesiosis","bullets":["Company will not re-submit IND for Phase IIB study (ACLR8-LR) of tafenoquine in mild-to-moderate COVID-19 after FDA feedback made U.S. enrollment unfeasible.","Shifts focus to ARAKODA (tafenoquine) commercialization for malaria prophylaxis and preparation for Phase IIA study in hospitalized babesiosis patients.","ARAKODA sales increased 150% in Q2 2023 vs Q2 2022; plans to appoint chief commercial officer and submit pre-IND meeting request for babesiosis in Q4 2023.","FDA advice indicated placebo-controlled study allowed only when nirmatrelvir/ritonavir is not clinically appropriate, making patient recruitment very challenging."],"urls":{"canonical":"https://secwatch.observer/filing/0001013762-23-003541","json":"https://secwatch.observer/filing/0001013762-23-003541.json","markdown":"https://secwatch.observer/filing/0001013762-23-003541.md","text":"https://secwatch.observer/filing/0001013762-23-003541.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1946563/000101376223003541/0001013762-23-003541-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1946563/000101376223003541/ea186616-8k_60degrees.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T01:12:21.153857+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}